Cardiology Today Current Issue

The following articles appeared in the print edition of Cardiology Today.

Table of Contents

• PCSK9 inhibitors poised for breakthrough as new cholesterol-lowering therapy
• Thrombosis and anticoagulation: Ten recent, clinically relevant publications Stephan Moll, MD
• FDA warns of potentially fatal heart rhythm associated with azithromycin
• FDA advisory panel voted in favor of approval of MitraClip
• Endovascular therapy not superior to standard treatment for stroke
• Midwall fibrosis predicted death risk in LVEF patients
• Massachusetts General Hospital launches Institute for Heart, Vascular and Stroke Care
• ASTRONAUT: Aliskiren did not benefit hospitalized HF patients
• CHAMPION PHOENIX: Cangrelor outperforms clopidogrel during PCI
• Eplerenone improved CV outcomes in STEMI patients
• HPS2-THRIVE: Niacin therapy not beneficial for vascular disease
• MACE lower with double kissing crush than culotte stenting
• PREVAIL: Watchman device promising for stroke prevention in nonvalvular AF
• RED-HF: Darbepoetin alfa failed to improve systolic HF, anemia
• SELECT-ACS: Inclacumab reduced myocardial damage after PCI for non-STEMI
• STREAM: Early fibrinolysis as effective as angioplasty
• TACT: High-dose vitamins plus chelation therapy may be beneficial
• TERISA: Ranolazine reduced angina in patients with diabetes
• The pharmacist’s role in reducing admissions, improving outcomes in HF Daniel F. Miller, PharmD, BCPS
• ARMYDA-9 CAROTID
• ASTRONAUT
• CHAMPION PHOENIX
• DIG
• PEITHO
• PRAGUE-6
• STREAM
• TERISA